Home > Products > CD3 & EGFR
> Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (Fv-IgG)
Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (Fv-IgG) (CAT#: BSDG-077)
Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD3 IgG with similar domains from an anti-EGFR antibody via short peptide linkers, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (Fv-IgG) (BSDG-077). Click the button below to contact us or submit your feedback about this product.